IBA Signs Contract to Install Cyclone® 70 System in Arizona, USA
Cyclotron to be dedicated to the production of radiopharmaceuticals for diagnosing and treating critical illnesses worldwide
Louvain-la-Neuve, Belgium, June 8th 2018 - IBA (Ion Beam Applications S.A., EURONEXT), a world’s leading provider of solutions for the diagnosis and treatment of cancer, today announces it has signed a formal contract with the Arizona Isotopes Science Research Corp. (AZI) to install a Cyclone® 70 system in Arizona, USA. The installation of the system is worth between $16 and $20 million to IBA and the project is fully financed.
Bruno Scutnaire, Head of RadioPharma Solutions at IBA, commented: “We are delighted to see the Arizona Isotopes Science Research Corp. selecting our Cyclone® 70 system. This will enable the continuous production of isotopes used in the diagnosis of cardiovascular diseases and other critical illnesses. IBA is the only provider of radiopharmaceutical cyclotrons with the expertise and experience to construct such a high energy system.”
“We selected IBA for its leading technology and unique know-how in developing high energy 70 MeV cyclotrons,” said Dr Sheldon Trubatch, AZI Corporate Secretary. “IBA’s expertise will allow us to reach our objectives of supplying medical isotopes for the diagnosis and treatment of critical illnesses worldwide.”
The Cyclone® 70 is a high energy and high current proton industrial cyclotron. IBA has sold three other Cyclone® 70 systems to date: the Cyclone® 70 ( multiparticle version cyclotron) which has been fully operational for radioisotope production and research in France (Arronax project, Nantes) since 2011; the Cyclone® 70 at Zevacor Molecular in the USA is fully operational since 2015; and a third Cyclone®70 currently under installation in Moscow, Russia.
***ENDS***
Getekend en gefinancierd Toppie